SCYX Split History

SCYNEXIS (SCYX) has 1 split in our SCYX split history database. The split for SCYX took place on July 17, 2020. This was a 1 for 10 reverse split, meaning for each 10 shares of SCYX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.

When a company such as SCYNEXIS conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the SCYX split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into SCYNEXIS shares, starting with a $10,000 purchase of SCYX, presented on a split-history-adjusted basis factoring in the complete SCYX split history.

Growth of $10,000.00 Without Dividends Reinvested
Start date:	05/06/2014
End date:	06/07/2023
Start price/share:	$84.00
End price/share:	$2.54
Dividends collected/share:	$0.00
Total return:	-96.98%
Average Annual Total Return:	-31.94%
Starting investment:	$10,000.00
Ending investment:	$302.32
Years:	9.09

About SCYNEXIS

SCYNEXIS is a biotechnology company. Co. is developing its main product candidate, ibrexafungerp, as an intravenous/oral agent for multiple fungal indications in both the community and hospital settings. The U.S. Food and Drug Administration has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis, respectively. Co. is also continuing on-going clinical studies of ibrexafungerp for multiple indications, including the treatment of life-threatening invasive fungal infections in hospitalized patients. According to our SCYX split history records, SCYNEXIS has had 1 split.